Medicamen Biotech Ltd vs Windlas Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 280.1 as of 05 May 15:30 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2022 to 35.8 on March 2025 . This represents a CAGR of 31.42% over 4 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2022 to ₹ 2176 crore on March 2025 . This represents a CAGR of 47.65% over 4 years The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The revenue of Windlas Biotech Ltd for the Dec '25 is ₹ 237.67 crore as compare to the Sep '25 revenue of ₹ 226.04 crore. This represent the growth of 5.15% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The ebitda of Windlas Biotech Ltd for the Dec '25 is ₹ 28.95 crore as compare to the Sep '25 ebitda of ₹ 32.2 crore. This represent the decline of -10.09% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The net profit of Windlas Biotech Ltd changed from ₹ 13.48 crore to ₹ 15 crore over 7 quarters. This represents a CAGR of 6.30% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2022 to 20.04 % on March 2025 . This represents a CAGR of 0.31% over 4 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About Windlas Biotech Ltd

Windlas Biotech Limited, formerly known as Windlas Biotech Private Limited was incorporated in 2001.
The Company got converted from a Private Limited to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'.
A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun. The Company is engaged in manufacturing and trading of pharmaceutical products.
Their manufacturing plants are located at Dehradun in Uttarakhand.
It has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The Company commenced operations at Dehradun Plant -IV in 2010.

FAQs for the comparison of Medicamen Biotech Ltd and Windlas Biotech Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or Windlas Biotech Ltd?

Market cap of Medicamen Biotech Ltd is 351 Cr while Market cap of Windlas Biotech Ltd is 1,811 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and Windlas Biotech Ltd?

The stock performance of Medicamen Biotech Ltd and Windlas Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and Windlas Biotech Ltd?

As of May 5, 2026, the Medicamen Biotech Ltd stock price is INR ₹258.95. On the other hand, Windlas Biotech Ltd stock price is INR ₹858.1.

How do dividend payouts of Medicamen Biotech Ltd and Windlas Biotech Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and Windlas Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.